Literature DB >> 11044111

Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.

P N Nyambi1, A Nádas, H A Mbah, S Burda, C Williams, M K Gorny, S Zolla-Pazner.   

Abstract

In order to protect against organisms that exhibit significant genetic variation, polyvalent vaccines are needed. Given the extreme variability of human immunodeficiency virus type 1 (HIV-1), it is probable that a polyvalent vaccine will also be needed for protection from this virus. However, to understand how to construct a polyvalent vaccine, serotypes or immunotypes of HIV must be identified. In the present study, we have examined the immunologic relatedness of intact, native HIV-1 primary isolates of group M, clades A to H, with human monoclonal antibodies (MAbs) directed at epitopes in the V3, C5, and gp41 cluster I regions of the envelope glycoproteins, since these regions are well exposed on the virion surface. Multivariate analysis of the binding data revealed three immunotypes of HIV-1 and five MAb groups useful for immunotyping of the viruses. The analysis revealed that there are fewer immunotypes than genotypes of HIV and that clustering of the isolates did not correlate with either genotypes, coreceptor usage (CCR5 and CXCR4), or geographic origin of the isolates. Further analysis revealed distinct MAb groups that bound preferentially to HIV-1 isolates belonging to particular immunotypes or that bound to all three immunotypes; this demonstrates that viral immunotypes identified by mathematical analysis are indeed defined by their immunologic characteristics. In summary, these results indicate (i) that HIV-1 immunotypes can be defined, (ii) that constellations of epitopes that are conserved among isolates belonging to each individual HIV-1 immunotype exist and that these distinguish each of the immunotypes, and (iii) that there are also epitopes that are routinely shared by all immunotypes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044111      PMCID: PMC110941          DOI: 10.1128/jvi.74.22.10670-10680.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Spectral mapping, a technique for classifying biological activity profiles of chemical compounds.

Authors:  P J Lewi
Journal:  Arzneimittelforschung       Date:  1976

2.  Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy.

Authors:  D R Kilpatrick; B Nottay; C F Yang; S J Yang; E Da Silva; S Peñaranda; M Pallansch; O Kew
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

3.  Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes.

Authors:  J Louwagie; F E McCutchan; M Peeters; T P Brennan; E Sanders-Buell; G A Eddy; G van der Groen; K Fransen; G M Gershy-Damet; R Deleys
Journal:  AIDS       Date:  1993-06       Impact factor: 4.177

Review 4.  Evolution and polymorphism of poliovirus genomes.

Authors:  R Crainic; O Kew
Journal:  Biologicals       Date:  1993-12       Impact factor: 1.856

5.  Further evidence of the presence of genetically aberrant HIV-1 strains in Cameroon and Gabon.

Authors:  W Janssens; J N Nkengasong; L Heyndrickx; K Fransen; P M Ndumbe; E Delaporte; M Peeters; J L Perret; A Ndoumou; C Atende
Journal:  AIDS       Date:  1994-07       Impact factor: 4.177

6.  Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

Authors:  P N Nyambi; H A Mbah; S Burda; C Williams; M K Gorny; A Nádas; S Zolla-Pazner
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  Multivariate analysis of human immunodeficiency virus type 1 neutralization data.

Authors:  P N Nyambi; J Nkengasong; P Lewi; K Andries; W Janssens; K Fransen; L Heyndrickx; P Piot; G van der Groen
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations.

Authors:  C T D'Angio; W M Maniscalco; M E Pichichero
Journal:  Pediatrics       Date:  1995-07       Impact factor: 7.124

9.  Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype.

Authors:  J R Mascola; J Louwagie; F E McCutchan; C L Fischer; P A Hegerich; K F Wagner; A K Fowler; J G McNeil; D S Burke
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

10.  Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.

Authors:  P N Nyambi; M K Gorny; L Bastiani; G van der Groen; C Williams; S Zolla-Pazner
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more
  25 in total

Review 1.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.

Authors:  Kausik Chakraborty; Venuka Durani; Edward Roshan Miranda; Michael Citron; Xiaoping Liang; William Schleif; Joseph G Joyce; Raghavan Varadarajan
Journal:  Biochem J       Date:  2006-11-01       Impact factor: 3.857

4.  Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.

Authors:  Vincent Holl; Maryse Peressin; Thomas Decoville; Sylvie Schmidt; Susan Zolla-Pazner; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.

Authors:  Nina R Derby; Zane Kraft; Elaine Kan; Emma T Crooks; Susan W Barnett; Indresh K Srivastava; James M Binley; Leonidas Stamatatos
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

7.  Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120.

Authors:  Tommy Tong; Keiko Osawa; James E Robinson; Ema T Crooks; James M Binley
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

8.  SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?

Authors:  Robert Sealy; Xiaoyan Zhan; Timothy D Lockey; Louis Martin; James Blanchard; Vicki Traina-Dorge; Julia L Hurwitz
Journal:  Curr HIV Res       Date:  2009-09       Impact factor: 1.581

9.  Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.

Authors:  Susan Zolla-Pazner; Sandra Cohen; Abraham Pinter; Chavdar Krachmarov; Terri Wrin; Shixia Wang; Shan Lu
Journal:  Virology       Date:  2009-07-26       Impact factor: 3.616

10.  Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.

Authors:  Timothy Cardozo; James Swetnam; Abraham Pinter; Chavdar Krachmarov; Arthur Nadas; David Almond; Susan Zolla-Pazner
Journal:  AIDS Res Hum Retroviruses       Date:  2009-04       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.